top of page

Chung-Pu (Paul) Wu  (吳宗圃)

Biography

Chung-Pu (Paul) Wu is a Professor of Pharmacology at Chang Gung University, one of the leading research universities in Taiwan. Wu earned his undergraduate degrees with First Class Honours and his Master of Science (M.Sc.) degree from the University of Cape Town, South Africa, where he pioneered the discovery of novel antimalarial drugs using drug screening platforms and combinatorial chemistry. He completed his Ph.D. at the University of Cambridge, United Kingdom, followed by postdoctoral training at the National Cancer Institute, NIH, USA.

Dr. Wu's current research investigates the role of ATP-binding cassette (ABC) drug transporters in developing multidrug resistance (MDR) in cancer patients. His work includes designing novel inhibitors of human ABCB1 (P-glycoprotein; MDR1) and ABCG2 (BCRP; MXR), as well as developing new therapeutic strategies to resensitize multidrug-resistant cancer cells to chemotherapeutic agents.

 

Areas of Expertise

Multidrug Resistance Mechanisms; ATP-binding Cassette Proteins; Protein Kinase Inhibitors;

Medicinal Chemistry; Natural Products Chemistry

​

Contact

E-mail: wuchung@mail.cgu.edu.tw
Phone: +886-3-2118800 (ext. 3754 or 3751)
Mail: Department of Physiology and Pharmacology, College of Medicine,

Chang Gung University, Tao-Yuan 33302, Taiwan

​

台灣 333 桃園市 龜山區 文化一路 259 號

第一醫學大樓 5 樓 A 區 健康老化中心

E-Mail：wuchung@mail.cgu.edu.tw

聯絡電話：(03)211-8800  ext. 3754

Profile.jpg

Citations: 3919

H-index: 33

ORCID: 0000-0002-2434-3361

Current Position
(現職)

Professor, Head of Department,
Department of Physiology and Pharmacology,
Chang Gung University

長庚大學醫學院 生理暨藥理學科   教授   主任
台北長庚醫院 婦產科 合聘研究員

Education and Professional Experience: 

(學經歷)
​

  • Postdoctoral Researcher, National Cancer Institute (NCI), National Institutes of Health (NIH), USA

  • Postdoctoral Researcher, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan

  • Visiting Scholar, National Cancer Institute (NCI), National Institutes of Health (NIH), USA

  • Ph.D. in Pharmacology, University of Cambridge, UK

  • ​

  • 美國國家衛生院 癌症研究中心 (NCI, NIH, USA) 博士後研究員

  • 台灣國家衛生研究院 生物技術與藥物研究組 博士後研究員

  • 美國國家衛生院 癌症研究中心 (NCI, NIH, USA) 訪問學人

  • 英國劍橋大學 (University of Cambridge, UK) 藥理學 博士

​

​

Service:

(學術服務)

​

  • Ad hoc reviewer of   ACS Chemical Biology

  • Ad hoc reviewer of   Advances and Applications in                                                                  Bioinformatics and Chemistry

  • Ad hoc reviewer of   Acta Pharmaceutica Sinica B

  • Ad hoc reviewer of   Biochimica et Biophysica Acta BBA                                                         Biomembranes

  • Ad hoc reviewer of   Biochemical Pharmacology

  • Ad hoc reviewer of   BioMed Research International

  • Ad hoc reviewer of   Biomedicine & Pharmacotherapy

  • Ad hoc reviewer of   BMC Cancer

  • Ad hoc reviewer of   Cancer Communications

  • Ad hoc reviewer of   Cancer Drug Resistance

  • Ad hoc reviewer of   Cancer Letters

  • Ad hoc reviewer of   Cancer Research

  • Ad hoc reviewer of   Cell Biochemistry and Biophysics

  • Ad hoc reviewer of   Current Pharmaceutical                                                                           Biotechnology

  • Ad hoc reviewer of   Current Medicinal Chemistry

  • Ad hoc reviewer of   Drug Metabolism and Disposition

  • Ad hoc reviewer of   Drug Resistance Updates

  • Ad hoc reviewer of   European Journal of Medicinal Chemistry

  • Ad hoc reviewer of   Frontiers in Pharmacology

  • Ad hoc reviewer of   Heliyon

  • Ad hoc reviewer of   International Journal of Pharmacology

  • Ad hoc reviewer of   iScience

  • Ad hoc reviewer of   Journal of Cancer Research Updates

  • Ad hoc reviewer of   Journal of Cellular and Molecular                                                           Medicine

  • Ad hoc reviewer of   Journal of Pharmaceutics

  • Ad hoc reviewer of   Journal of Photochemistry and                                                               Photobiology B: Biology

  • Ad hoc reviewer of   Marine Drugs

  • Ad hoc reviewer of   Med

  • Ad hoc reviewer of   Molecular Cancer

  • Ad hoc reviewer of   Molecular Cancer Therapeutics

  • Ad hoc reviewer of   Molecular Pharmaceutics

  • Ad hoc reviewer of   Molecules

  • Ad hoc reviewer of   New Journal of Science

  • Ad hoc reviewer of   Pharmaceutical Research

  • Ad hoc reviewer of   Research

  • Ad hoc reviewer of   The Scientific World Journal

  • Ad hoc reviewer of   The Journal of Biological Chemistry

  • Ad hoc reviewer of   The Journal of the National Cancer                                                       Institute

  • Ad hoc reviewer of   Theranostics

  • Ad hoc reviewer of   Toxicology and Applied Pharmacology

 

​

​

Selected Peer-Reviewed Publications
(代表性學術著作)

  1. B-H Lin, Y-C Li, M Murakami, Y-S Wu, Y-H Huang, T-H Hung, S. V. Ambudkar, C-P Wu*. Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2. Biomedicine & Pharmacotherapy (2024) Nov; 180: 117542. (IF = 6.9; Journal Rank in PHARMACOLOGY & PHARMACY = 15/354)

  2. Y-C Li, Y-C Lee, M Murakami, Y-H Huang, T-H Hung, Y-S Wu, S. V. Ambudkar, C-P Wu*. The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug efflux. Biomedicine & Pharmacotherapy (2024) Nov; 180: 117554. (IF = 6.9; Journal Rank in PHARMACOLOGY & PHARMACY = 15/354) 

  3. Y-C Li, S-H Hsiao, M Murakami, Y-H Huang, Y-T Chang, T-H Hung, Y-S Wu, S. V. Ambudkar, C-P Wu*. The epidermal growth factor receptor inhibitor mobocertinib resensitizes multidrug-resistant cancer cells by attenuating the human ATP-binding cassette subfamily B member 1 and subfamily G member 2. ACS Pharmacology & Translational Science (2023) Dec; 7(1): 161-175. (IF = 6.0; Journal Rank in CHEMISTRY, MEDICINAL = 7/70)

  4. C-P Wu*, S-H Hsiao, Y-S Wu. Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2. Drug Resistance Updates (2023) Nov; 71: 101011. (IF = 24.3; Journal Rank in PHARMACOLOGY & PHARMACY = 2/278)

  5. C-P Wu*, Y-J Hsieh, H-Y Tseng, et al. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomedicine & Pharmacotherapy (2022) Oct;154:113663. (IF = 7.5; Journal Rank in PHARMACOLOGY & PHARMACY = 22/278)

  6. C-P Wu*, M Murakami, Y-S Wu, et al. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine & Pharmacotherapy (2022) May;149:112922. (IF = 7.5; Journal Rank in PHARMACOLOGY & PHARMACY = 22/278)

  7. C-P Wu*, Y-Q Li, T-H Hung, et al. Sophoraflavanone G resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to chemotherapeutic drugs. Journal of Natural Products (2021) Sep 24;84(9):2544-2553. (IF = 5.1; Journal Rank in PLANT SCIENCES = 33/239)

  8. C-P Wu*, T-H Hung, S Lusvarghi, et al. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochemical Pharmacology (2021) Jun;188:114516. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  9. C-P Wu*, C-Y Hung, S. Lusvarghi, et al. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cells. Biochemical Pharmacology (2020) Oct;180:114137. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  10. C-P Wu*, S Lusvarghi, S-H Hsiao, et al. Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products (2020) May 22;83(5):1461-1472. (IF = 5.1; Journal Rank in PLANT SCIENCES = 33/239)

  11. C-P Wu*, S. Lusvarghi, P-J Tseng, et al. MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research (2020) Jan 1;10(1):164-178. (IF = 5.3; Journal Rank in ONCOLOGY = 70/241)

  12. C-P Wu*, S Lusvarghi, J-C Wang, et al. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics (2019) Jul 1;16(7):3040-3052. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  13. S-H Hsiao, S Lusvarghi, Y-H Huang, S. V. Ambudkar, S-C Hsu, C-P Wu*. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters (2019) Mar 31;445:34-44. (IF = 9.7; Journal Rank in ONCOLOGY = 32/317)

  14. S-H Hsiao, M Murakami, N Yeh, Y-Q Li, T-H Hung, Y-S Wu, S. V. Ambudkar, C-P Wu*. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Cancer Letters (2018) Oct 10;434:81-90. (IF = 9.7; Journal Rank in ONCOLOGY = 32/317)

  15. C-P Wu*, M Murakami, S-H Hsiao, et al. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters (2018) Oct 1;433:259-272. (IF = 9.7; Journal Rank in ONCOLOGY = 32/317)

  16. C-P Wu*, Y-J Hsieh, M Murakami, et al. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochemical Pharmacology (2018) Sep; 155: 316-325. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  17. C-W Huang, W-C Hsieh, S-T Hsu, Y-W Lin, Y-H Chung, W-C Chang, H Chiu, YH Lin, C-P Wu, T-C Yen, F-T Huang. The use of PET imaging for prognostic integrin α2β1 phenotyping to detect non-small cell lung cancer and monitor drug resistance responses. Theranostics (2017) Sep 20;7(16):4013-4028. (IF = 12.4; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 8/136)

  18. C-P Wu*, SH Hsiao, M Murakami, et al. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Letters (2017) Nov 28;409:56-65. (IF = 9.7; Journal Rank in ONCOLOGY = 32/317)

  19. C-P Wu*, SH Hsiao, M Murakami, et al. Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. Molecular Pharmaceutics (2017) Aug 7;14(8):2805-2814. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 43/362)

  20. C-P Wu*, M Murakami, S-H Hsiao, et al. Overexpression of ATP-binding cassette sub-family G member 2 confers resistance to phosphatidylinositol 3-kinase inhibitor PF-4989216 in cancer cells. Molecular Pharmaceutics (2017) Jul 3;14(7):2368-2377. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  21. Y-J Lin, W-C Shyu, C-W Chang, C-C Wang, C-P Wu, et al. Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression. Theranostics (2017) Mar 5;7(5):1177-1191. (IF = 12.4; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 8/136)

  22. SH Hsiao, YJ Lu, CC Yang, WC Tuo, YQ Li, YH Huang, CH Hsieh, TH Hung, C-P Wu*. Hernandezine, a bisbenzylisoquinoline alkaloid with selective inhibitory activity against multidrug resistance-linked ATP-binding cassette drug transporter ABCB1. Journal of Natural Products (2016) Aug 26;79(8):2135-42. (IF = 5.1; Journal Rank in PLANT SCIENCES = 33/239)

  23. SH Hsiao, YJ Lu, YQ Li, YH Huang, CH Hsieh, C-P Wu*. Osimertinib (AZD9291) attenuates the function of multidrug resistance linked ATP-binding cassette transporter ABCB1 in vitro. Molecular Pharmaceutics (2016) Jun 6;13(6):2117-25. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  24. C-P Wu*, YJ Hsieh, SH Hsiao, et al. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. Molecular Pharmaceutics (2016). Mar 7;13(3):784-94. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  25. J-P Gillet, JB Andersen, JP Madigan, S Varma, RK Bagni, K Powell, WE Burgan, C-P Wu, AM Calcagno, SV. Ambudkar, SS Thorgeirsson, MM Gottesman. A gene expression signature associated with overall survival in patients with hepatocellular carcinoma suggests a new treatment strategy. Molecular Pharmacology (2016) Feb;89(2):263-72. (IF = 3.6; Journal Rank in PHARMACOLOGY & PHARMACY = 115/278)

  26.  WL Chen, CC Wang, YJ Lin, C-P Wu, CH Hsieh. Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. Journal of Translational Medicine (2015) Dec 28;13(1):389. (IF = 7.4; Journal Rank in MEDICINE, RESEARCH & EXPERIMENTAL = 29/136)

  27. C-P Wu*, C-H Hsieh, S-H Hsiao, et al. Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI 6727), a selective inhibitor of polo-Like kinase 1. Molecular Pharmaceutics (2015) Nov 2;12(11):3885-95. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  28. C-H Hsieh, Y-J Lin, C-P Wu, et al. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. Clinical Cancer Research (2015) Jan, 21(2): 460-70. (IF = 11.5; Journal Rank in ONCOLOGY = 22/241)

  29. C-P Wu*, S-H Hsiao, C-Y Su, et al. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochemical Pharmacology (2014) Dec 15;92(4):567-76. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  30. C-P Wu*, S-H Hsiao, S-Y Luo, et al. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1. Molecular Pharmaceutics (2014) Oct 6;11(10):3727-36. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  31. C-P Wu, SV Ambudkar. The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B. (2014) Apr;4(2):105-11. (IF = 14.5; Journal Rank in PHARMACOLOGY & PHARMACY = 5/278)

  32. C-P Wu*, S-H Hsiao, H-M Sim, et al. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of polo-like kinase 1. Biochemical Pharmacology (2013) Oct 1;86(7):904-13. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  33. Y Fukuda, K Takenaka, A Sparreboom, SB Cheepala, C-P Wu, S Ekins, SV Ambudkar, JD Schuetz. HIV protease inhibitors interact with ABCC4/MRP4: a basis for unanticipated enhanced cytotoxicity. Molecular Pharmacology (2013) Sep, 84(3): 361-71. (IF = 3.6; Journal Rank in PHARMACOLOGY & PHARMACY = 115/278)

  34. C-P Wu*, H-M Sim, Y-H Huang, Y-C Liu, S-H Hsiao, H-W Cheng, Y-Q Li, SV Ambudkar and S-C Hsu. Overexpression of ATP-Binding Cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochemical Pharmacology (2013) Feb, 85(3): 325-334. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  35. C-W Chou, C-C Wang, C-P Wu, et al. Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro-Oncology (2012) Oct, 14(10): 1227-38. (IF = 15.9; Journal Rank in CLINICAL NEUROLOGY = 4/212)

  36. Y-H Kuang, JP Patel, K Sodani, C-P Wu, et al. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology (2012) Sep, 84(6): 766-774. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  37. C-H Hsieh, C-P Wu, H-T Lee, et al. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in Glioblastoma multiforme. Free Radical Biology and Medicine (2012) Aug, 53(4): 649-658. (IF = 7.4; Journal Rank in ENDOCRINOLOGY & METABOLISM = 19/145)

  38. H-M Lin, J-C Wang, H-S Hu, P-S Wu, C-C Yang, C-P Wu, et al. Resistance analysis and characterization of a Thiazole analogue, BP008, as a potent Hepatitis C Virus NS5A inhibitor. Antimicrobial Agents and Chemotherapy (2012) Jan, 56(1): 44-53. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 62/277)

  39. C-P Wu, C-H Hsieh and Y-S Wu. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Molecular Pharmaceutics (2011) Dec, 8(6): 1996-2011. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  40. HM Sim, C-P Wu, SV Ambudkar and ML Go. In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochemical Pharmacology (2011) Aug, 82(11): 1562-1571. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  41. S Shukla, AP Skoumbourdis, MJ Walsh, AMS Hartz, KL Fung, C-P Wu, et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (Nilotinib): Evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Molecular Pharmaceutics (2011) Aug, 8(4): 1292-1302. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 61/278)

  42. MB Lucia, M Handley, J-P Gillet, C-P Wu, et al. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's Sarcoma cells. British Journal of Cancer (2011) Aug, 105(4): 513-522. (IF = 8.8; Journal Rank in ONCOLOGY = 36/241)

  43. C-P Wu, S Ohnuma, SV Ambudkar. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Current Pharmaceutical Biotechnology (2011) Apr;12(4):609-20. (IF = 2.8; Journal Rank in PHARMACOLOGY & PHARMACY = 172/277)

  44. C-C Yang, Y-C Hsieh, S-J Lee, S-H Wu, C-L Liao, C-H Tsao, Y-S Chao, C-P Wu* and A Yueh. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a High-Throughput Screening assay. Antimicrobial Agents and Chemotherapy (2011) Jan, 55(1): 229-238. (IF = 4.9; Journal Rank in PHARMACOLOGY & PHARMACY = 62/277)

  45. I Abraham, S Jain, C-P Wu, et al. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology (2010) Nov, 80(10): 1497-506. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  46. AM Calcagno, CD Salcido, J-P Gillet, C-P Wu, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem-cell characteristics. JNCI-Journal of the National Cancer Institute (2010) Nov, 102(21): 1637-52. (IF = 10.3; Journal Rank in ONCOLOGY = 32/241)

  47. Y-J Mi, Y-J Liang, H Huang, H-Y Zhao, C-P Wu, F Wang, L-Y Tao, C-Z Zhang, C-L Dai, AK Tiwari, X-X Ma, KKW To, SV Ambudkar, Z-S Chen, L-W Fu. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Research (2010) Oct, 70(20): 7981-91. (IF = 11.2; Journal Rank in ONCOLOGY = 25/241)

  48. M Kucka, K Kretschmannova, T Murano, C-P Wu, et al. Dependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductance. Molecular Pharmacology (2010) Feb, 77(2):270-9. (IF = 3.6; Journal Rank in PHARMACOLOGY & PHARMACY = 115/278)

  49. C-L Dai, Y-J Liang, L-M Chen, X Zhang, W-J Deng, X-D Su, Z Shi, C-P Wu, C Ashby Jr, S Akiyama, SV Ambudkar, Z-S Chen and L-W Fu. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology (2009) Aug, 78(4): 355-64. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  50. JN Orina, AM Calcagno, C-P Wu, et al. Evaluation of current methods used to analyze the expression profiles of ABC transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics (2009) Jul, 8(7): 2057-2066. (IF = 5.7; Journal Rank in ONCOLOGY = 62/241)

  51. C-L Dai#, AK Tiwari#, C-P Wu#, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Research (2008) Oct, 68: 7905-7914. (# co-first authors) (IF = 11.2; Journal Rank in ONCOLOGY = 25/241)

  52. C-P Wu, AM Calcagno, SV Ambudkar. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Current Molecular Pharmacology (2008) Jun;1(2):93-105. (IF = 2.7; Journal Rank in PHARMACOLOGY & PHARMACY = 177/278)

  53. AM Calcagno, JM Fostel, KW To, SE Martin, KJ Chewning, C-P Wu, SE Bates, NJ Caplen and S.V. Ambudkar. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British Journal of Cancer (2008) May, 98: 1515-1524. (IF = 8.8; Journal Rank in ONCOLOGY = 36/241)

  54. S Shukla, C-P Wu, S.V. Ambudkar. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opinion on Drug Metabolism & Toxicology (2008) Feb;4(2):205-23. (IF = 4.3; Journal Rank in PHARMACOLOGY & PHARMACY = 88/278)

  55. C-P Wu, S Shukla, AM Calcagno, et al. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter. Molecular Cancer Therapeutics (2007) Dec, 6: 3287-3296. (IF = 5.7; Journal Rank in ONCOLOGY = 62/241)

  56. S Shukla, C-P Wu and SV Ambudkar. The napthoquinones, vitamin K3 and its structural analog plumbagin, are substrates of the multidrug resistance-linked ABC drug transporter ABCG2. Molecular Cancer Therapeutics (2007) Dec, 6: 3279-3286. (IF = 5.7; Journal Rank in ONCOLOGY = 62/241)

  57. J Golin, ZN Kon, C-P Wu, et al. Complete inhibition of the Pdr5p multidrug efflux pump ATPase activity by its transport substrate clotrimazole suggests that ATP as well as GTP may be used as an energy source. Biochemistry-US (2007) Nov 46: 13109-13119. (IF = 2.9; Journal Rank in BIOCHEMISTRY & MOLECULAR BIOLOGY = 192/285)

  58. AM Calcagno, I-W Kim, C-P Wu, et al. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Current Drug Delivery (2007) Oct, 4: 324-333. (IF = 2.4; Journal Rank in PHARMACOLOGY & PHARMACY = 197/278)

  59. AM Calcagno, KJ Chewning, C-P Wu and SV Ambudkar. Plasma membrane calcium ATPase (PMCA4): A housekeeper for RT-PCR relative quantification of polytopic membrane proteins. BMC Molecular and Cell Biology (2006) Sep, 7(29): 1-10. (IF = 4.619; Journal Rank in BIOCHEMISTRY & MOLECULAR BIOLOGY = 132/296)

  60. W Chearwae, C-P Wu, H-Y Chu, et al. Curcuminoids purified from turmeric powder modulate the function of human Multidrug Resistance Protein 1 (ABCC1). Cancer Chemotherapy and Pharmacology (2006) Feb, 14: 1-13. (IF = 3.0; Journal Rank in PHARMACOLOGY & PHARMACY = 158/278)

  61. C-P Wu, AM Calcagno, SB Hladky, et al. Modulatory effect of plant polyphenols on human multidrug resistance proteins 1, 4 and 5. FEBS Journal (2005) Sep, 272: 4725-40. (IF = 5.4; Journal Rank in BIOCHEMISTRY & MOLECULAR BIOLOGY = 73/285)

  62. C-P Wu, DA van Schalkwyk, D Taylor, et al. Reversal of chloroquine resistance in Plasmodium falciparum by 9H-Xanthene derivatives. International Journal of Antimicrobial Agents (2005) Aug, 26: 170-175. (IF = 10.8; Journal Rank in PHARMACOLOGY & PHARMACY = 11/278)

  63. C-P Wu, A Klokouzas, SB Hladky, et al. Interactions of mefloquine with ABC transporters, MRP1 (ABCC1) and MRP4 (ABCC4), in human erythrocyte cell membranes. Biochemical Pharmacology (2005) Aug, 70: 500-510. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  64. C-P Wu, H Woodcock, SB Hladky, et al. cGMP transport across human erythrocyte membranes: factors influencing its ATP-dependent uptake into inside-out membrane vesicles. Biochemical Pharmacology (2005) Apr, 69: 1257-62. (IF = 5.8; Journal Rank in PHARMACOLOGY & PHARMACY = 39/278)

  65. A Klokouzas, T Tiffert, DA van Schalkwyk, C-P Wu, HW van Veen, MA Barrand, SB Hladky. Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochemical and Biophysical Research Communications (2004) Aug, 321: 197-201. (IF = 3.1; Journal Rank in BIOPHYSICS = 33/70)

  66. A Klokouzas, C-P Wu, HW van Veen, et al. cGMP and glutathione-conjugate transport in human erythrocytes. European Journal of Biochemistry (FEBS Journal) (2003) Sep, 270: 3696-3708. (IF = 5.4; Journal Rank in BIOCHEMISTRY & MOLECULAR BIOLOGY = 73/285)

bottom of page